Access to Prescription Digital Therapeutics Act of 2023
Summary
Access to Prescription Digital Therapeutics Act of 2023
This bill provides for Medicare and Medicaid coverage of prescription digital therapeutics (i.e., software applications that are used to prevent, manage, or treat medical conditions). The Centers for Medicare & Medicaid Services must establish a Medicare payment methodology for payments to manufacturers that takes into account certain factors (e.g., ongoing use); manufacturers must report specified information about private payors, subject to civil penalties.
Lifecycle of the Bill
Considered as unfinished business. (consideration: CR H2390)
Mar 4, 2026
Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 384 - 40 (Roll no. 81).
Mar 4, 2026
On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 384 - 40 (Roll no. 81).
Mar 4, 2026
Motion to reconsider laid on the table Agreed to without objection.
Mar 4, 2026
Mr. Westerman moved to suspend the rules and pass the bill.
Mar 3, 2026
Considered under suspension of the rules. (consideration: CR H2359-2362; text: CR H2359-2361)
Mar 3, 2026
DEBATE - The House proceeded with forty minutes of debate on S. 723.
Mar 3, 2026
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Mar 3, 2026
Received in the House.
Dec 15, 2025
Held at the desk.
Dec 15, 2025
